Table 2: Variables in death and survival patients with COVID-19.
| Variables | Normal range | All 28 | Death 11 (42.9) | Survival 17 (57.1) | P |
| Median ± IQR | |||||
| Male | 18 (64.3) | 9 (81.8) | 9 (52.9) | 0.124† | |
| Duration of Symptoms, days | 0.794† | ||||
| Range | 2-35 | 3-21 | 2-35 | ||
| Mean | 9.5 ± 7.4 | 9.0 ± 5.0 | 9.8 ± 8.7 | ||
| Median | 7 | 9 | 7 | ||
| Length of ICU, days | 0.258† | ||||
| Range | 1-38 | 1-38 | 3-30 | ||
| Mean | 13.3 ± 9.7 | 10.6 ± 10.4 | 14.9 ± 9.1 | ||
| Median | 10 | 8 | 12 | ||
| WBC (× 109/L), Mean ± SD | 04-10 | 10.4 ± 5.0 | 12.0 ± 3.6 | 9.4 ± 5.6 | 0.186† |
| Increased | 12 (42.9) | 7 (63.6) | 5 (29.4) | 0.081† | |
| L (×109/L), Mean ± SD | 0.8-4.0 | 0.7 ± 0.3 | 0.7 ± 0.4 | 0.8 ± 0.3 | 0.776† |
| Decreased | 19 (67.9) | 8 (72.7) | 11 (64.7) | 0.493† | |
| HGB (g/L), Mean ± SD | 110-160 | 129.9 ± 20.0 | 137.3 ± 19.6 | 125.1 ± 19.3 | 0.117† |
| Decreased | 6 (21.4) | 2 (18.1) | 4 (23.5) | 0.561† | |
| PLT (×109/L), Mean ± SD | 100-300 | 221.1 ± 111.9 | 153.3 ± 59.6 | 265.1 ± 117.1 | 0.003†* |
| Decreased | 2 (7.1) | 2 (18.1) | 0 (0) | 0.146† | |
| PCT (ug/L) | 0-0.5 | 0.2 ± 0.2 | 0.3 ± 0.2 | 0.2 ± 0.1 | 0.029¶* |
| Increased | 3 (10.7) | 2 (18.1) | 1 (5.9) | 0.336† | |
| BNP (ng/L)§ | 0-300 | 781.4 ± 2018.4 | 916.5 ± 3000.3 | 275.5 ± 654.3 | 0.157¶ |
| Increased | 14 (77.7) | 9 (100) | 5 (55.6) | 0.041†* | |
| ALT (U/L) | 0-40 | 37.0 ± 23.0 | 37.0 ± 27.0 | 36.0 ± 25.5 | 0.495¶ |
| Increased | 12 (42.9) | 5 (45.5) | 7 (41.2) | 0.565† | |
| AST (U/L) | 0-40 | 35.0 ± 33.0 | 41.0 ± 37.0 | 35.0 ± 30.0 | 0.706¶ |
| Increased | 11 (39.3) | 6 (54.5) | 5 (29.4) | 0.175† | |
| ALB (g/L) | 30-50 | 29.9 ± 6.4 | 26.9 ± 2.9 | 32.3 ± 5.3 | 0.002¶* |
| Decreased | 16 (57.1) | 10 (90.9) | 6 (35.3) | 0.005†* | |
| TBIL (umol/L) | 0-22 | 17.4 ± 12.5 | 26.4 ± 18.3 | 13.2 ± 9.0 | 0.045¶* |
| Increased | 9 (32.1) | 6 (54.5) | 3 (17.6) | 0.052† | |
| BUN (mmol/L) | 2.5-9.4 | 6.8 ± 4.1 | 7.2 ± 7.2 | 6.2 ± 4.1 | 0.115¶ |
| Increased | 7 (25) | 3 (41.7) | 4 (23.5) | 0.581† | |
| CK (U/L) | 24-204 | 84.0 ± 157.0 | 118.0 ± 402.0 | 81.0 ± 157.0 | 0.588¶ |
| Increased | 7 (25) | 3 (27.3) | 4 (23.5) | 0.581† | |
| CK-MB (U/L) | 0-24 | 14.0 ± 11.0 | 17.0 ± 18.0 | 11.0 ± 9.5 | 0.028¶* |
| Increased | 5 (17.9) | 4 (36.4) | 1 (5.9) | 0.062† | |
| LDH (U/L) | 109-245 | 409.0 ± 233.0 | 563.0 ± 248.0 | 380.0 ± 136.5 | 0.002¶* |
| Increased | 26 (92.9) | 11 (100) | 15 (88.2) | 0.633† | |
| K (mmol/L) | 3.5-5.6 | 3.9 ± 1.1 | 3.3 ± 1.1 | 4.1 ± 0.8 | 0.034¶* |
| Decreased | 8 (28.6) | 6 (54.5) | 2 (11.8) | 0.022†* | |
| Na (mmol/L) | 130-150 | 137.0 ± 5.0 | 139.0 ± 3.0 | 135.0 ± 4.0 | 0.042¶* |
| Decreased | 2 (7.1) | 1 (9.1) | 1 (5.9) | 0.640† | |
| PT (s) | Sep-14 | 12.4 ± 2.7 | 14.3 ± 2.2 | 11.8 ± 2.0 | 0.005¶* |
| Increased | 7 (25) | 6 (54.5) | 1 (5.9) | 0.007†* | |
| APTT (s) | 22-38 | 26.5 ± 9.7 | 31.6 ± 11.0 | 26.2 ± 7.3 | 0.063¶ |
| Increased | 2 (7.1) | 2 (18.1) | 0 (0) | 0.146† | |
| INR | 0.8-1.5 | 1.06 ± 0.26 | 1.2 ± 0.2 | 1.0 ± 0.2 | 0.006¶* |
| Increased | 1 (3.6) | 1 (9.1) | 0 (0) | 0.393† | |
| D-D (ug/ml) | 0-1 | 3.0 ± 6.32 | 4.3 ± 12.4 | 3.0 ± 5.4 | 0.689¶ |
| Increased | 19 (67.9) | 7 (63.6) | 12 (70.6) | 0.507† | |
| LAC (mmol/L) | 0.5-2.0 | 1.4 ± 0.8 | 1.5 ± 1.4 | 1.3 ± 0.9 | 0.187¶ |
| Increased | 7 (25) | 4 (36.4) | 3 (17.6) | 0.249† |
(%) is the percentage of the proportion in this group.
*P < 0.05; †Chi-square test; †Independent sample t-test; ¶Mann-Whitney U test; §10 cases were unavailable.